Two Cases of Refractory Thrombocytopenia in Systemic Lupus Erythematosus that Responded to Intravenous Low-Dose Cyclophosphamide

다국어 초록 (Multilingual Abstract)

Treatment of thrombocytopenia in systemic lupus erythematosus (SLE) is considered in cases of current bleeding, severe bruising, or a platelet count below 50,000/μL.

Corticosteroid is the first choice of medication for inducing remission, and immunosuppressive agents can be added when thrombocytopenia is refractory to corticosteroid or recurs despite it. We presented two SLE patients with thrombocytopenia who successfully induced remission after intravenous administration of low-dose cyclophosphamide (CYC) (500 mg fixed dose, biweekly for 3 months), followed by azathioprine (AZA) or mycophenolate mofetil (MMF). Both patients developed severe thrombocytopenia in SLE that did not respond to pulsed methylprednisolone therapy, and started the intravenous low-dose CYC therapy. In case 1, the platelet count increased to 50,000/μL after the first CYC infusion, and remission was maintained with low dose prednisolone and AZA. The case 2 achieved remission after three cycles of CYC, and the remission continued with low dose prednisolone and MMF.

참고문헌 (Reference)

1 Arnal C, "Treatment of severe immune thrombocytopenia associated with systemic lupus erythematosus: 59 cases" 29 : 75-83, 2002

2 Roach BA, "Treatment of refractory, systemic lupus erythematosus- associated thrombocytopenia with intermittent low-dose intravenous cyclophosphamide" 36 : 682-684, 1993

3 Gorman C, "This house believes that low-dose intravenous cyclophosphamide is superior to standard high-dose regimes for treatment of lupus nephritis" 44 : 398-401, 2005

4 Hepburn AL, "The management of peripheral blood cytopenias in systemic lupus erythematosus" 49 : 2243-2254, 2010

5 Houssiau FA, "The 10-year follow-up data of the Euro-Lupus Nephritis Trial comparing low-dose and high-dose intravenous cyclophosphamide" 69 : 61-64, 2010

6 Alarcon-Segovia D, "Splenectomy has a limited role in the management of lupus with thrombocytopenia" 29 : 1-2, 2002

7 Hall S, "Splenectomy does not cure the thrombocytopenia of systemic lupus erythematosus" 102 : 325-328, 1985

8 Vasoo S, "Refractory immune thrombocytopenia in systemic lupus erythematosus: response to mycophenolate mofetil" 12 : 630-632, 2003

9 Reiner A, "Pulse cyclophosphamide therapy for refractory autoimmune thrombocytopenic purpura" 85 : 351-358, 1995

10 Sultan SM, "Prevalence, patterns of disease and outcome in patients with systemic lupus erythematosus who develop severe haematological problems" 42 : 230-234, 2003

11 You YN, "Outcome of splenectomy for thrombocytopenia associated with systemic lupus erythematosus" 240 : 286-292, 2004

12 Contreras G, "Maintenance therapies for proliferative lupus nephritis: mycophenolate mofetil, azathioprine and intravenous cyclophosphamide" 14 : 33-38, 2005

13 Boumpas DT, "Intermittent cyclophosphamide for the treatment of autoimmune thrombocytopenia in systemic lupus erythematosus" 112 : 674-677, 1990